{"id":4674,"date":"2025-03-31T18:12:16","date_gmt":"2025-03-31T18:12:16","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/saquinavir-txt\/"},"modified":"2025-03-31T18:12:16","modified_gmt":"2025-03-31T18:12:16","slug":"saquinavir-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/saquinavir-txt\/","title":{"rendered":"saquinavir.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nProtease inhibitor:Treatment of HIV infection in combination with other antiviral drugs

DOSE IN NORMAL RENAL FUNCTION <\/H3>With low dose ritonavir: 1 g twice daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :670.8<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :98<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <4<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :10<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :13.2

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in normal renal function
  • HDF\/high flux &nbsp :Not dialysed. Dose as in normal renal function
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Antibacterials: rifampicin and rifabutin can reduce saquinavir levels by 80% and 40% respectively (metabolism accelerated); increased hepatoxicity with rifampicin; concentration possibly increased by quinupristin\/dalfopristin; avoid with telithromycin in severe renal and hepatic failure\n
  • Antidepressants: concentration reduced by St John\u2019s wort \u2013 avoid\n
  • Anti-epileptics: carbamazepine, phenobarbital, primidone and phenytoin can reduce saquinavir levels\n
  • Antimalarials: avoid concomitant use with artemether\/lumefantrine\n
  • Antipsychotics: possibly increased risk of ventricular arrhythmias with pimozide and sertindole \u2013 avoid concomitant use; possibly inhibits aripiprazole metabolism \u2013 reduce aripiprazole dose\n
  • Antivirals: tipranavir and efavirenz can reduce saquinavir levels; nelfinavir can cause an increase in levels of both nelfinavir and saquinavir; concentration increased by atazanavir, indinavir, lopinavir and ritonavir; reduced darunavir concentration
    Anxiolytics and hypnotics: midazolam plasma concentration possibly increased (prolonged sedation) \u2013 avoid\n
  • Ciclosporin: concentration of both drugs increasedCilostazol: concentration of cilostazol possibly increased \u2013 avoid concomitant use\n
  • Ergot alkaloids: risk of ergotism \u2013 avoid Lipid-lowering drugs: increased risk of myopathy with simvastatin \u2013 avoid; possibly increased myopathy with atorvastatin
    Omeprazole: AUC of saquinavir increased by 82% (increased risk of toxicity)\n
  • Tacrolimus: possibly increased tacrolimus concentration \u2013 may need to reduce dose

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>Administer within 2 hours after meal

    OTHER INFORMATION <\/H4>
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Protease inhibitor:Treatment of HIV infection in combination with<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4674","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4674"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4674\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}